Insder Trading Filing: John Mcmahon, VP – Chief Financial Officer of Heska Corp (NASDAQ:HSKA) Just Unloaded Shares

November 29, 2016 - By Nellie Frank

Insder Trading Filing: John Mcmahon, VP   Chief Financial Officer of Heska Corp (NASDAQ:HSKA) Just Unloaded Shares

John Mcmahon Insider Sell

VP – Chief Financial Officer John Mcmahon of Heska Corp, sold some 1,999 of the Colorado-based Heska Corp shares having a market value of $131,219 US Dollars with an average of $65.6 stock price for each share. The chance of this transaction staying a secret is quite small as it’s new, with the VP – Chief Financial Officer now possessing 43 shares – that is 0.0006% of the Company’s total market capitalization.

Heska Corp (NASDAQ:HSKA) Ratings Coverage

Out of 3 analysts covering Heska Corp (NASDAQ:HSKA), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Heska Corp has been the topic of 4 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The rating was downgraded by Gabelli to “Hold” on Thursday, August 4. The stock of Heska Corp (NASDAQ:HSKA) earned “Neutral” rating by CL King on Friday, April 1. The firm has “Hold” rating by TheStreet given on Tuesday, August 25. Benchmark initiated Heska Corp (NASDAQ:HSKA) on Tuesday, November 29 with “Buy” rating.

Insitutional Activity: The institutional sentiment decreased to 1.36 in Q2 2016. Its down 0.18, from 1.54 in 2016Q1. The ratio worsened, as 6 funds sold all Heska Corp shares owned while 29 reduced positions. 24 funds bought stakes while 30 increased positions. They now own 4.56 million shares or 4.63% more from 4.36 million shares in 2016Q1.

Nationwide Fund Advsrs owns 3,833 shares or 0% of their US portfolio. The California-based California State Teachers Retirement Sys has invested 0% in Heska Corp (NASDAQ:HSKA). Schwab Charles Inv Management accumulated 0% or 16,417 shares. The California-based Eam Ltd Liability has invested 0.37% in Heska Corp (NASDAQ:HSKA). The Massachusetts-based Bogle Lp De has invested 0.11% in Heska Corp (NASDAQ:HSKA). Dalton Greiner Hartman Maher And accumulated 15,112 shares or 0.03% of the stock. Royal Bancorporation Of Canada owns 380 shares or 0% of their US portfolio. Legal General Grp Incorporated Plc last reported 1,016 shares in the company. Goldman Sachs Gru has invested 0% of its portfolio in Heska Corp (NASDAQ:HSKA). Us Savings Bank De accumulated 56,246 shares or 0.01% of the stock. Pembroke Management Limited holds 0.47% of its portfolio in Heska Corp (NASDAQ:HSKA) for 137,103 shares. Analytic Investors Ltd Com last reported 36,955 shares in the company. Grace White New York last reported 230,964 shares in the company. Eagle Glob Advisors Lc owns 19,080 shares or 0.02% of their US portfolio. New York State Common Retirement Fund accumulated 0% or 5,800 shares.

Insider Transactions: Since July 1, 2016, the stock had 0 insider purchases, and 15 insider sales for $6.68 million net activity. Shares for $240,008 were sold by Wilson Kevin S. on Wednesday, July 6. $262,642 worth of shares were sold by NAPOLITANO JASON A on Thursday, September 1. Asakowicz Steve also sold $305,000 worth of Heska Corp (NASDAQ:HSKA) shares. Lippincott Rod sold 5,000 shares worth $324,258. McGinley Michael J had sold 9,998 shares worth $601,051. McMahon John sold 137 shares worth $7,028.

About 113,084 shares traded hands or 11.16% up from the average. Heska Corp (NASDAQ:HSKA) has risen 132.87% since April 26, 2016 and is uptrending. It has outperformed by 127.61% the S&P500.

Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The company has a market cap of $461.86 million. The Firm focuses on the canine and feline companion animal health markets. It has a 54.48 P/E ratio. The Company’s divisions include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.

According to Zacks Investment Research, “Heska Corporation is focused on the discovery, development and marketing of companion animal health products. In addition to manufacturing certain of companion animal products, the company’s primary manufacturing subsidiary, Diamond Animal Health, Inc., also manufactures animal health vaccine products which are marketed and distributed by third parties. In addition to manufacturing veterinary allergy products for marketing and sale by the company, subsidiaries, Center Laboratories, Inc. and CMG-Heska Allergy Products S.A., also manufacture and sell human allergy products.”

Analysts await Heska Corp (NASDAQ:HSKA) to report earnings on March, 2. They expect $0.37 earnings per share, up 32.14% or $0.09 from last year’s $0.28 per share. HSKA’s profit will be $2.53M for 45.62 P/E if the $0.37 EPS becomes a reality. After $0.45 actual earnings per share reported by Heska Corp for the previous quarter, Wall Street now forecasts -17.78% negative EPS growth.

Another recent and important Heska Corp (NASDAQ:HSKA) news was published by Prnewswire.com which published an article titled: “Heska Announces Executive Promotions to Further Growth Initiatives” on September 29, 2016.

HSKA Company Profile

Heska Corporation, incorporated on March 27, 1997, develops, makes, markets, sells and supports veterinary products. The Firm is focused on the canine and feline companion animal health markets. The Firm operates in two divisions, which include Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It sells veterinary diagnostic and other specialty veterinary products. The Company’s offerings include blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>